Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India · Delayed Price · Currency is INR | Market Cap | 114.83B +71.0% |
| Revenue (ttm) | 48.29B +17.5% |
| Net Income | 3.64B +14.7% |
| EPS | 23.76 +14.7% |
| Shares Out | 153.10M |
| PE Ratio | 31.57 |
| Forward PE | 23.97 |
| Dividend | 1.00 (0.13%) |
| Ex-Dividend Date | Jul 3, 2026 |
| Volume | 177,141 |
| Open | 769.85 |
| Previous Close | 769.85 |
| Day's Range | 748.00 - 772.15 |
| 52-Week Range | 409.30 - 838.80 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 915.00 (+22.0%) |
| Earnings Date | Nov 3, 2026 |
About NSE:AKUMS
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-s... [Read more]
Financial Performance
In fiscal year 2026, NSE:AKUMS's revenue was 43.61 billion, an increase of 5.84% compared to the previous year's 41.21 billion. Earnings were 2.55 billion, a decrease of -24.54%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AKUMS stock is "Strong Buy." The 12-month stock price target is ₹915.00, which is an increase of 22.00% from the latest price.
News
Akums Drugs and Pharmaceuticals Transcript: Q2 26/27
Q2 FY27 revenue grew 31.9% YoY and EBITDA 106%, led by CDMO volume growth above 20%. Expansion plans include Baddi capacity and international contracts, while API losses and input-cost volatility remain key considerations.
Akums Drugs and Pharmaceuticals Quarterly report: Q2 2027
Akums Drugs and Pharmaceuticals has published its Q2 2027 quarterly earnings report on November 3, 2026.
Akums Drugs and Pharmaceuticals Slides: Q2 2027
Akums Drugs and Pharmaceuticals has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 3, 2026.
Akums Drugs and Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 saw strong revenue and EBITDA growth, led by the CDMO segment's double-digit volume gains and improved API prices. The company expanded its manufacturing footprint with the Oriflame India acquisition and maintains a robust cash position, supporting future growth and capacity expansion.
Akums Drugs and Pharmaceuticals Quarterly report: Q1 2027
Akums Drugs and Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 10, 2026.
Akums Drugs and Pharmaceuticals Slides: Q1 2027
Akums Drugs and Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.
Akums Drugs and Pharmaceuticals announces 22nd AGM and annual report availability
Akums Drugs and Pharmaceuticals Limited has announced that its 22nd Annual General Meeting (AGM) will be held on Friday, July 10, 2026, at 11:00 A.M. via Video Conferencing (VC) or…
Akums Drugs and Pharmaceuticals reports 79.95% turnover from pharma manufacturing
Akums Drugs and Pharmaceuticals Limited has reported that 79.95% of its turnover for the financial year 2025-26 was derived from the manufacturing of pharmaceutical products and CDMO services. This si...
Akums announces 22nd AGM and dividend details in newspaper advertisement
Akums Drugs and Pharmaceuticals has announced details regarding its 22nd Annual General Meeting (AGM) and dividend distribution through a newspaper advertisement. The announcement was published in Bus...
Akums Drugs and Pharmaceuticals Transcript: Q4 25/26
FY 2026 saw resilient growth with revenue up 5.8% and strong CDMO performance, despite API headwinds. International expansion accelerated with major contracts in Europe and Zambia, while cash flow and liquidity remained robust. CapEx and dividend plans support future growth.
Akums Drugs and Pharmaceuticals Quarterly report: Q4 2026
Akums Drugs and Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 18, 2026.
Akums Drugs and Pharmaceuticals Slides: Q4 2026
Akums Drugs and Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 18, 2026.
Akums Drugs and Pharmaceuticals Annual report: Q4 2026
Akums Drugs and Pharmaceuticals has published its Q4 2026 annual report on May 18, 2026.
Akums Drugs Q4 Results: Net profit falls 45.7% YoY to Rs 81.3 crore, revenue up 9.7%
Akums Drugs and Pharmaceuticals reported its Q4FY26 earnings with mixed performance, as the company posted a sharp decline in net profit despite healthy growth in revenue and operating performance. Th...
Akums Drugs and Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw robust revenue and EBITDA growth, led by strong CDMO and international branded formulation performance, with margin expansion and improved cash flows. Key projects in Europe and Zambia are progressing, and automation initiatives are underway.
Akums Drugs and Pharmaceuticals Quarterly report: Q3 2026
Akums Drugs and Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 16, 2026.
Akums Drugs and Pharmaceuticals Slides: Q3 2026
Akums Drugs and Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 16, 2026.
Akums Drugs shares jump over 6% after Q3 results; Revenue rises 14.8% YoY to Rs 1,160 crore
Shares of Akums Drugs and Pharmaceuticals Ltd surged more than 6% in trade after the company reported its consolidated results...
Veradermics, Incorporated IPOs Tomorrow, Here's What You Need To Know
Veradermics, Incorporated (NYSE: MANE) IPO will take place February, 04 on the NYSE exchange under the ticker MANE. The company is offering shares at an expected price between $14.00 and $16.00 per s...
Akums Drugs subsidiary faces additional Rs 1.8 crore GST penalty in Gujarat
Akums Drugs and Pharmaceuticals on Tuesday, December 16, informed stock exchanges that its wholly owned subsidiary, Maxcure Nutravedics Limited, has...
Akums Drugs and Pharmaceuticals Transcript: Q2 25/26
Revenue declined 1.5% YoY to INR 1,018 crore in Q2 FY 2026, with EBITDA margin dropping to 9.3% due to API price declines and new facility overheads. Strategic initiatives include a Zambia JV and a major European CDMO contract, with strong cash reserves supporting future growth.
Akums Drugs and Pharmaceuticals Quarterly report: Q2 2026
Akums Drugs and Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 14, 2025.
Akums Drugs and Pharmaceuticals Slides: Q2 2026
Akums Drugs and Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 14, 2025.
Akums Drugs incorporates wholly owned subsidiary in Malta, Europe
Akums Drugs and Pharmaceuticals Limited has announced the incorporation of its wholly owned subsidiary in Malta, Europe, named Akums Healthcare...
Akums Drugs and Pharmaceuticals Transcript: Q1 25/26
Revenue and profitability grew in Q1 FY26, led by CDMO and R&D milestones, despite API price declines. Cash position is strong, with a EUR 100 million EU contract advance and robust free cash flow. Mid single-digit growth is targeted for FY26, with European expansion underway.